EDIT 241220 1.50P (EDIT241220P1500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

EDIT241220P1500

Watchlist

0.17
+0.02+13.33%

15min DelayTrading Dec 19 09:48 ET

0.17High0.05Low

Intraday

5D
Daily

News

Clear Street Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $4
Moomoo NewsDec 19 05:36 ET · Ratings
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Cuts Target Price to $5
Moomoo NewsDec 16 08:33 ET · Ratings
Evercore ISI Group Maintains Outperform on Editas Medicine, Lowers Price Target to $5
BenzingaDec 16 08:29 ET · Ratings
JP Morgan Downgrades Editas Medicine to Underweight
BenzingaDec 16 08:23 ET
J.P. Morgan Downgrades Editas Medicine(EDIT.US) to Sell Rating
Moomoo NewsDec 16 06:32 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)
TipRanksDec 16 01:10 ET · Ratings

Comments

Broke Trader

Dec 12 15:08

Editas Medicine Inc - Expected Costs of $55 Million to $70 Million

$Editas Medicine (EDIT.US)$

Jaguar8

Dec 12 15:01

NEWS

$Editas Medicine (EDIT.US)$
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
Thursday, 12th December at 4:00 pm
• Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues:
◦ Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell...

Stock_Drift

Dec 9 14:23

$Editas Medicine (EDIT.US)$

Trytosaveabit

Oct 22 06:22

$Editas Medicine (EDIT.US)$ Editas Medicine Announced In Vivo Preclinical Proof Of Concept Data Of Hematopoietic Stem And Progenitor Cell Editing And Fetal Hemoglobin Induction In Humanized Mice Engrafted With Human Hematopoietic Stem Cells And Lacking Their Own Hematopoietic Cells
Benzinga· 2 mins ago
The Company observed high levels of editing of the HBG1/2 promoter, leveraging clinically validated upregulation strategy, utilizing a novel and Editas-proprietary targeted lipid nanoparticle (tLNP...

Jaguar8

Oct 3 23:44

AH NEWS TODAY

$Editas Medicine (EDIT.US)$
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Editas Medicine (Nasdaq: EDIT) has announced a $57 million upfront cash payment from DRI Healthcare Trust in exchange for certain future license fees and payments under its Cas9 license agreement with Vertex Pharmaceuticals. This non-dilutive capital will support Editas Medicine's pipeline development and strategic priorities.
The deal includes up to 100% of future ann...